# OnCo record sapu-nano (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/sapu-nano/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "sapu-nano" ;
  schema:name "Sapu Nano"@en ;
  schema:alternateName "SAPU NANO (US) LLC"@en ;
  schema:description "Sapu Nano reformulates existing cancer drugs as extremely small particles that can be given into a vein. Its first product, Sapu003, is an intravenous form of the mTOR inhibitor everolimus, in an early trial in several advanced solid tumours."@en ;
  schema:url <https://onco.cc/companies/sapu-nano/>, <https://sapunano.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://sapunano.com/>, <https://sapunano.com/sapu003/>, <https://sapunano.com/news/>, <https://clinicaltrials.gov/study/NCT07369505> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/neuroendocrine/>, <https://onco.cc/cancers/hcc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/> ;
  onco:targets <https://onco.cc/targets/mtor/> .